Undressing the fungal cell wall/cell membrane - the antifungal drug targets

Current Pharmaceutical Design

Volumn 19, Issue 20, 2013, Pages 3738-3747

  Tada, Rui ^a   Latgé, Jean Paul ^a   Aimanianda, Vishukumar ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

Antifungal drugs; Azole; Candida albicans; Cell wall; Chitin; Echinocandin; Fumigatus; Glucan; Mannan; Polysaccharide

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; TERBINAFINE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ASPERGILLUS; CANDIDA; CELL MEMBRANE; DRUG SYNTHESIS; DRUG TARGETING; FUNGAL CELL WALL; FUNGAL MEMBRANE; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDIASIS; CELL MEMBRANE; CELL WALL; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; POLYSACCHARIDES;

EID: 84878652157     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319200012     Document Type: Review

References (122)

1. Bassetti M, Mikulska M. Bench-to-bedside review: therapeutic management of invasive candidiasis in the intensive care unit. Crit Care 2010; 14: 244.
2. Mezger M, Einsele H. Genetic susceptibility to infections with Aspergillus fumigatus. Crit Rev Microbiol 2010; 36: 168-77.
3. Muller C, Riederer M. Plant surface properties in chemical ecology. J Chem Ecol 2005; 31: 2621-51.
4. Vollmer W, Bertsche U. Murein (peptidoglycan) structure, architecture and biosynthesis in Escherichia coli. Biochim Biophys Acta 2008; 1778: 1714-34.
5. Vollmer W, Blanot D, de Pedro MA. Peptidoglycan structure and architecture. FEMS Microbiol Rev 2008; 32: 149-67.
6. Chopra I, Hesse L, O'Neill AJ. Exploiting current understanding of antibiotic action for discovery of new drugs. Symp Ser Soc Appl Microbiol2002;: 4S-15S.
7. Green DW. The bacterial cell wall as a source of antibacterial targets. Expert Opin Ther Targets 2002; 6: 1-19.
8. Odds FC, Brown AJ, Gow NA. Antifungal agents: mechanisms of action. Trends Microbiol 2003; 11: 272-9.
9. Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 1999; 12: 501-17.
10. Alcazar-Fuoli L, Mellado E, Garcia-Effron G, Lopez JF, Grimalt JO, et al. Ergosterol biosynthesis pathway in Aspergillus fumigatus. Steroids 2008; 73: 339-47.
11. Daum G, Tuller G, Nemec T, Hrastnik C, Balliano G, et al. Systematic analysis of yeast strains with possible defects in lipid metabolism. Yeast 1999; 15: 601-14.
12. Carrillo-Munoz AJ, Giusiano G, Ezkurra PA, Quindos G. Antifungal agents: mode of action in yeast cells. Rev Esp Quimioter 2006; 19: 130-9.
13. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-60.
14. Laniado-Laborin R, Cabrales-Vargas MN. Amphotericin B: side effects and toxicity. Rev Iberoam Micol 2009; 26: 223-7.
15. Johnson RH, Einstein HE. Amphotericin B and coccidioidomycosis. Ann N Y Acad Sci 2007; 1111: 434-41.
16. Wingard JR, Kubilis P, Lee L, et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999; 29: 1402-7.
17. Martin MT, Gavalda J, Lopez P, et al. Efficacy of high doses of liposomal amphotericin B in the treatment of experimental aspergillosis. J Antimicrob Chemother 2003; 52: 1032-4.
18. Richardson MD, Warnock DW. Antifungal drugs. Fungal infection Diagnosis and management Blackwell. 2000; pp. 29-79.
19. Chicella MF, Woodruff ED, Desai MM. A review of Candida prophylaxis in the neonatal intensive care population. J Pediatr Pharmacol Ther 2011; 16: 237-45.
20. Semis R, Polacheck I, Segal E. Nystatin-intralipid preparation: characterization and in vitro activity against yeasts and molds. Mycopathologia 2010; 169: 333-341.
21. te Welscher YM, Jones L, van Leeuwen MR, et al. Natamycin inhibits vacuole fusion at the priming phase via a specific interaction with ergosterol. Antimicrob Agents Chemother 2010; 54: 2618-25.
22. Lass-Florl C. Triazole antifungal agents in invasive fungal infections: a comparative review. Drugs 2011; 71: 2405-19.
23. Haylett AK, Felton S, Denning DW, Rhodes LE. Voriconazoleinduced photosensitivity: photobiological assessment of a case series of 12 patients. Br J Dermatol. 2012
24. Aperis G, Alivanis P. Posaconazole: a new antifungal weapon. Rev Recent Clin Trials 2011; 6: 204-19.
25. Meletiadis J, Antachopoulos C, Stergiopoulou T, et al. Differential fungicidal activities of amphotericin B and voriconazole against Aspergillus species determined by microbroth methodology. Antimicrob Agents Chemother 2007; 51: 3329-37.
26. Nowosielski M, Hoffmann M, Wyrwicz LS, et al. Detailed Mechanism of Squalene Epoxidase Inhibition by Terbinafine. J Chem Inf Model 2011.
27. Nowosielski M, Hoffmann M, Wyrwicz LS, et al. Detailed mechanism of squalene epoxidase inhibition by terbinafine. J Chem Inf Model 2011; 51: 455-62.
28. Schiraldi GF, Colombo MD, Harari S, et al. Terbinafine in the treatment of non-immunocompromised compassionate cases of bronchopulmonary aspergillosis. Mycoses 1996; 39: 5-12.
29. Polak A. Mode of action of morpholine derivatives. Ann N Y Acad Sci 1988; 544: 221-8.
30. Marcireau C, Guilloton M, Karst F. In vivo effects of fenpropimorph on the yeast Saccharomyces cerevisiae and determination of the molecular basis of the antifungal property. Antimicrob Agents Chemother 1990; 34: 989-93.
31. Meyer V, Damveld RA, Arentshorst M, et al. Survival in the presence of antifungals: genome-wide expression profiling of Aspergillus niger in response to sublethal concentrations of caspofungin and fenpropimorph. J Biol Chem 2007; 282: 32935-48.
32. Ryder N. Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Derm 1992; 126: 2-7.
33. Chamilos G, DP. K. Update on antifungal drug resistance mechanisms of Aspergillus fumigatus. Drug Resist Updat 2005; 8: 344-58.
34. Latge JP. The cell wall: a carbohydrate armour for the fungal cell. Mol Microbiol 2007; 66: 279-90.
35. Traxler P, Gruner J, Auden JA. Papulacandins, a new family of antibiotics with antifungal activity, I. Fermentation, isolation, chemical and biological characterization of papulacandins A, B, C, D and E. J Antibiot (Tokyo) 1977; 30: 289-96.
36. Onishi J, Meinz M, Thompson J, et al. Discovery of novel antifungal (1,3)-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother 2000; 44: 368-77.
37. Raasch RH. Anidulafungin: review of a new echinocandin antifungal agent. Expert Rev Anti Infect Ther 2004; 2: 499-508.
38. Perlin DS. Current perspectives on echinocandin class drugs. Future Microbiol 2011; 6: 441-57.
39. Kurtz MB, Rex JH. Glucan synthase inhibitors as antifungal agents. Adv Protein Chem 2001; 56: 423-75.
40. Kartsonis N, DiNubile MJ, Bartizal K, et al. Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole. J Acquir Immune Defic Syndr 2002; 31: 183-7.
41. Posteraro B, Sanguinetti M, Fiori B, et al. Caspofungin activity against clinical isolates of azole cross-resistant Candida glabrata overexpressing efflux pump genes. J Antimicrob Chemother 2006; 58: 458-61.
42. Imhof A, Balajee SA, Marr KA. New methods to assess susceptibilities of Aspergillus isolates to caspofungin. J Clin Microbiol 2003; 41: 5683-8.
43. Espinel-Ingroff A. Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991). J Clin Microbiol 2003; 41: 403-9.
44. Bowman JC, Abruzzo GK, Anderson JW, et al. Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob Agents Chemother 2001; 45: 3474-81.
45. Kahn JN, Hsu MJ, Racine F, Giacobbe R, Motyl M. Caspofungin susceptibility in Aspergillus and non-Aspergillus molds: inhibition of glucan synthase and reduction of beta-D-1,3 glucan levels in culture. Antimicrob Agents Chemother 2006; 50: 2214-6.
46. Bowman JC, Hicks PS, Kurtz MB, et al. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother 2002; 46: 3001-12.
47. Nosanchuk JD. Current status and future of antifungal therapy for systemic mycoses. Recent Pat Antiinfect Drug Discov 2006; 1: 75-84.
48. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362: 1142-51.
49. Bormann AM, Morrison VA. Review of the pharmacology and clinical studies of micafungin. Drug Des Devel Ther 2009; 3: 295-302.
50. Kim R, Khachikian D, Reboli AC. A comparative evaluation of properties and clinical efficacy of the echinocandins. Expert Opin Pharmacother 2007; 8: 1479-92.
51. Temesgen Z, Barreto J, Vento S. Micafungin-the newest echinocandin. Drugs Today (Barc) 2009; 45: 469-78.
52. Chen SC, Slavin MA, Sorrell TC. Echinocandin antifungal drugs in fungal infections: a comparison. Drugs 2011; 71: 11-41.
53. Cappelletty D, Eiselstein-McKitrick K. The echinocandins. Pharmacotherapy 2007; 27: 369-88.
54. Vazquez JA, Sobel JD. Anidulafungin: a novel echinocandin. Clin Infect Dis 2006; 43: 215-22.
55. Zhang D, Miller MJ. Polyoxins and nikkomycins: progress in synthetic and biological studies. Curr Pharm Des 1999; 5: 73-99.
56. Ruiz-Herrera J, San-Blas G. Chitin synthesis as target for antifungal drugs. Curr Drug Targets Infect Disord 2003; 3: 77-91.
57. Hwang EI, Yun BS, Kim YK, et al. Phellinsin A, a novel chitin synthases inhibitor produced by Phellinus sp. PL3. J Antibiot (Tokyo) 2000; 53: 903-11.
58. Vijayakumar EK, Roy K, Chatterjee S, et al. Arthrichitin. A New Cell Wall Active Metabolite from Arthrinium phaeospermum. J Org Chem 1996; 61: 6591-3.
59. Albaugh D, Albert G, Bradford P, et al. Cell wall active antifungal compounds produced by the marine fungus Hypoxylon oceanicum LL-15G256. III. Biological properties of 15G256 gamma. J Antibiot (Tokyo) 1998; 51: 317-22.
60. Masubuchi K, Taniguchi M, Umeda I, et al. Synthesis and structure-activity relationships of novel fungal chitin synthase inhibitors. Bioorg Med Chem Lett 2000; 10: 1459-62.
61. Sudoh M, Yamazaki T, Masubuchi K, et al. Identification of a novel inhibitor specific to the fungal chitin synthase. Inhibition of chitin synthase 1 arrests the cell growth, but inhibition of chitin synthase 1 and 2 is lethal in the pathogenic fungus Candida albicans. J Biol Chem 2000; 275: 32901-5.
62. Anderson JB. Evolution of antifungal-drug resistance: mechanisms and pathogen fitness. Nature Reviews Microbiology 2005; 3: 547-56.
63. Verweij PE, Snelders E, Kema GH, Mellado E, Melchers WJ. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect Dis 2009; 9: 789-95.
64. Howard SJ, Arendrup MC. Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection. Med Mycol2010.
65. Snelders E, Huis In 't Veld RA, Rijs AJ, et al. Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl Environ Microbiol 2009; 75: 4053-7.
66. Tekaia F, Latge JP. Aspergillus fumigatus: saprophyte or pathogen? Curr Opin Microbiol 2005; 8: 385-92.
67. Ferreira ME, Colombo AL, Paulsen I, et al. The ergosterol biosynthesis pathway, transporter genes, and azole resistance in Aspergillus fumigatus. Med Mycol 2005; 43 Suppl 1: S313-9.
68. Martínez M, López-Ribot JL, Kirkpatrick WR, et al. Heterogeneous mechanisms of azole resistance in Candida albicans clinical isolates from an HIV-infected patient on continuous fluconazole therapy for oropharyngeal candidosis. J Antimicrob Chemother 2002; 49: 515-24.
69. Niimi K, Monk BC, Hirai A, et al. Clinically significant micafungin resistance in Candida albicans involves modification of a glucan synthase catalytic subunit GSC1 (FKS1) allele followed by loss of heterozygosity. J Antimicrob Chemother 2010; 65: 842-52.
70. Katiyar S, Pfaller M, Edlind T. Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob Agents Chemother 2006; 50: 2892-4.
71. Arendrup MC, Perkhofer S, Howard SJ, et al. Establishing in vitroin vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins. Antimicrob Agents Chemother 2008; 52: 3504-11.
72. Dorman CJ. Regulatory integration of horizontally-transferred genes in bacteria. Front Biosci 2009; 14: 4103-12.
73. Palmer KL, Kos VN, Gilmore MS. Horizontal gene transfer and the genomics of enterococcal antibiotic resistance. Curr Opin Microbiol 2010; 13: 632-9.
74. Selmecki AM, Dulmage K, Cowen LE, Anderson JB, J. B. Acquisition of Aneuploidy Provides Increased Fitness during the Evolution of Antifungal Drug Resistance. PLoS Genetics 2009; 5: e1000705.
75. Arendrup MC, Mavridou E, Mortensen KL, et al. Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence. PLoS One 2010; 5: e10080.
76. Walker LA, Gow NA, Munro CA. Fungal echinocandin resistance. Fungal Genet Biol 2010; 47: 117-26.
77. Lenardon MD, Lesiak I, Munro CA, Gow NA. Dissection of the Candida albicans class I chitin synthase promoters. Mol Genet Genomics 2009; 281: 459-71.
78. Mouyna I, Kniemeyer O, Jank T, et al. Members of protein Omannosyltransferase family in Aspergillus fumigatus differentially affect growth, morphogenesis and viability. Mol Microbiol 2010; 76: 1205-21.
79. Denning DW, Marr KA, Lau WM, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006; 53: 337-49.
80. Steinbach WJ, Stevens DA, Denning DW. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis 2003; 37 Suppl 3: S188-224.
81. Johnson MD, MacDougall C, Ostrosky-Zeichner L, Perfect JR, Rex JH. Combination antifungal therapy. Antimicrob Agents Chemother 2004; 48: 693-715.
82. Caillot D, Thiebaut A, Herbrecht R, et al. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer 2007; 110: 2740-6.
83. Lellek H, Waldenmaier D, Dahlke J, et al. Caspofungin plus posaconazole as salvage therapy of invasive fungal infections in immunocompromised patients. Mycoses 2011; 54: 39-44.
84. Aimanianda V, Latge JP. Problems and hopes in the development of drugs targeting the fungal cell wall. Expert Rev Anti Infect Ther 2010; 8: 359-64.
85. Mellado E, Dubreucq G, Mol P, et al. Cell wall biogenesis in a double chitin synthase mutant (chsG-/chsE-) of Aspergillus fumigatus. Fungal Genet Biol 2003; 38: 98-109.
86. Munro CA, Whitton RK, Hughes HB, et al. CHS8-a fourth chitin synthase gene of Candida albicans contributes to in vitro chitin synthase activity, but is dispensable for growth. Fungal Genet Biol 2003; 40: 146-58.
87. Lambou K, Perkhofer S, Fontaine T, Latge JP. Comparative functional analysis of the OCH1 mannosyltransferase families in As pergillus fumigatus and Saccharomyces cerevisiae. Yeast 2010; 27: 625-36.
88. Lamarre C, Beau R, Balloy V, et al. Galactofuranose attenuates cellular adhesion of Aspergillus fumigatus. Cell Microbiol 2009; 11: 1612-23.
89. Fung-Tomc JC, Bonner DP. Recent developments in pradimicinbenanomicin and triazole antibiotics. Expert Opin Investig Drugs 1997; 6: 129-45.
90. Henry C, Latge JP, Beauvais A. alpha1,3 glucans are dispensable in Aspergillus fumigatus. Eukaryot Cell 2012; 11: 26-9.
91. Muller FM, Seidler M, Beauvais A. Aspergillus fumigatus biofilms in the clinical setting. Med Mycol 2011; 49 Suppl 1: S96-100.
92. Iorio E, Torosantucci A, Bromuro C, et al. Candida albicans cell wall comprises a branched beta-D-(1-->6)-glucan with beta-D-(1-->3)-side chains. Carbohydr Res 2008; 343: 1050-61.
93. Kitamura A, Someya K, Hata M, Nakajima R, Takemura M. Discovery of a small-molecule inhibitor of {beta}-1,6-glucan synthesis. Antimicrob Agents Chemother 2009; 53: 670-7.
94. Takeshita H, Watanabe J, Kimura Y, et al. Novel pyridobenzimidazole derivatives exhibiting antifungal activity by the inhibition of beta-1,6-glucan synthesis. Bioorg Med Chem Lett 2010; 20: 3893-6.
95. Kuroyanagi J, Kanai K, Sugimoto Y, et al. Novel antifungal agents: triazolopyridines as inhibitors of beta-1,6-glucan synthesis. Bioorg Med Chem 2010; 18: 5845-54.
96. Armstrong-James D, Harrison TS. Immunotherapy for fungal infections. Curr Opin Microbiol 2012.
97. Magliani W, Conti S, Giovati L, et al. Antibody Peptide based antifungal immunotherapy. Front Microbiol 2012; 3: 190.
98. Polonelli L, Ciociola T, Magliani W, et al. Peptides of the constant region of antibodies display fungicidal activity. PLoS One 2012; 7: e34105.
99. Perruccio K, Tosti A, Burchielli E, et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood 2005; 106: 4397-406.
100. Montagnoli C, Perruccio K, Bozza S, et al. Provision of antifungal immunity and concomitant alloantigen tolerization by conditioned dendritic cells in experimental hematopoietic transplantation. Blood Cells Mol Dis 2008; 40: 55-62.
101. Safdar A, Hanna HA, Boktour M, et al. Impact of high-dose granulocyte transfusions in patients with cancer with candidemia: retrospective case-control analysis of 491 episodes of Candida species bloodstream infections. Cancer 2004; 101: 2859-65.
102. Torosantucci A, Bromuro C, Chiani P, et al. A novel glycoconjugate vaccine against fungal pathogens. J Exp Med 2005; 202: 597-606.
103. Torosantucci A, Chiani P, Bromuro C, et al. Protection by antibeta-glucan antibodies is associated with restricted beta-1,3 glucan binding specificity and inhibition of fungal growth and adherence. PLoS One 2009; 4: e5392.
104. Yuan RR, Casadevall A, Oh J, Scharff MD. T cells cooperate with passive antibody to modify Cryptococcus neoformans infection in mice. Proc Natl Acad Sci USA 1997; 94: 2483-2488.
105. Bozza S, Clavaud C, Giovannini G, et al. Immune sensing of Aspergillus fumigatus proteins, glycolipids, and polysaccharides and the impact on Th immunity and vaccination. J Immunol 2009; 183: 2407-14.
106. Wu X, Lipinski T, Carrel FR, Bailey JJ, DR. B. Synthesis and immunochemical studies on a Candida albicans cluster glycoconjugate vaccine. Org Biomol Chem 2007; 5: 3477-85.
107. Han Y, Ulrich MA, JE. C. Candida albicans mannan extract-protein conjugates induce a protective immune response against experimental candidiasis. J Infect Dis 1999; 179: 1477-84.
108. Nakamoto K, Tsukada I, Tanaka K, et al. Synthesis and evaluation of novel antifungal agents-quinoline and pyridine amide derivatives. Bioorg Med Chem Lett 2010; 20: 4624-6.
109. Nimrichter L, Rodrigues ML. Fungal glucosylceramides: from structural components to biologically active targets of new antimicrobials. Front Microbiol 2011; 2: 212.
110. Aaronson LR, Martin CE. Temperature-induced modifications of glycosphingolipids in plasma membranes of Neurospora crassa. Biochim Biophys Acta 1983; 735: 252-8.
111. Hakomori SI. Structure and function of glycosphingolipids and sphingolipids: recollections and future trends. Biochim Biophys Acta 2008; 1780: 325-46.
112. Lopez PH, Schnaar RL. Gangliosides in cell recognition and membrane protein regulation. Curr Opin Struct Biol 2009; 19: 549-57.
113. Bagnat M, Keranen S, Shevchenko A, Simons K. Lipid rafts function in biosynthetic delivery of proteins to the cell surface in yeast. Proc Natl Acad Sci USA 2000; 97: 3254-3259.
114. Staubach S, Hanisch FG. Lipid rafts: signaling and sorting platforms of cells and their roles in cancer. Expert Rev Proteomics 2011; 8: 263-77.
115. Rhome R, Singh A, Kechichian T, et al. Surface localization of glucosylceramide during Cryptococcus neoformans infection allows targeting as a potential antifungal. PLoS One 2011; 6: e15572.
116. Lamoth F, Juvvadi PR, Fortwendel JR, Steinbach WJ. Heat-shock protein 90 (Hsp90) is Required for Conidiation and Cell Wall Integrity in Aspergillus fumigatus. Eukaryot Cell 2012.
117. Singh SD, Robbins N, Zaas AK, et al. Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin. PLoS Pathog 2009; 5: e1000532.
118. Kim JH, Chan KL, Mahoney N, Campbell BC. Antifungal activity of redox-active benzaldehydes that target cellular antioxidation. Ann Clin Microbiol Antimicrob 2011; 10: 23.
119. Martinière A, Gayral P, Hawes C, J. R. Building bridges: formin1 of Arabidopsis forms a connection between the cell wall and the actin cytoskeleton. Plant J doi: 10.1111/j.1365-313X.2011.04497. 2011.
120. Mansfield BE OH, Oliver BG, Hoot SJ, Leyde SE, Hedstrom L, White TC. Azole drugs are imported by facilitated diffusion in Candida albicans and other pathogenic fungi. PLoS Pathog 2010; 6(9). e1001126.
121. Mehra T, Koberle M, Braunsdorf C, et al. Alternative approaches to antifungal therapies. Exp Dermatol 2012; 21: 778-82.
122. Pound MW, Townsend ML, Dimondi V, Wilson D, Drew RH. Overview of treatment options for invasive fungal infections. Med Mycol 2011; 49: 561-80.